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Objective: To examine the incidence of recurrent Clostridium difficile infection in patients with cystic ﬁbrosis (CF), including patients who had
undergone lung transplantation, and review clinical ﬁndings in hospitalized patients with C. difficile colitis.
Methods: A retrospective chart review was performed to examine the clinical presentation and management of patients with cystic ﬁbrosis (CF)
who received care at the University of Wisconsin Hospital and Clinics (UWHC) from 1994 to 2011 and were prospectively identiﬁed with C.
difficile colitis.
Results: Ten cases of C. difficile associated disease (CDAD) occurred in patients with CF followed by our Adult CF Center over a period of
17 years, and 4 patients were bilateral lung transplant recipients. Two of the lung transplant recipients had recurrent CDAD that lead to fulminant
pancolitis, surgical intervention, and shock. Two patients in the non-transplant group experienced recurrent C. difficile infection that led to
fulminant pancolitis with associated systemic inﬂammatory response syndrome and required colectomy.
Conclusions: C. difficile colitis can cause life threatening illness in patients with CF, and symptoms may be subtle and/or atypical and lead to
signiﬁcant delay in diagnosis. Patients with recurrent C. difficile colitis are at high risk of fatal outcome, and empiric therapy should be considered
for patients with previous C. difficile colitis even in the absence of disease when broad-spectrum antibiotics are given to treat bacterial infection.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Clostridium difficile; Pseudomembranous colitis; Cystic ﬁbrosis; Lung transplantation1. Introduction
Clostridium difficile infection primarily occurs in hospitalized
patients, causing as many as 3 million cases of diarrhea and colitis
per year [1]. Although the overall reported incidence of C. difficile
colitis in cystic fibrosis patients continues to be low, positive stool
cultures for C. difficile have been reported in up to 43% of
individuals with CF, but patients with toxin-producing strains tend
to remain asymptomatic [2]. According to Theunissen et al. [3]
patients with CF who were lung transplant recipients had a higher
risk of developing C. difficile infection and tended to present with
atypical clinical symptoms. Since 1996 multiple case review
studies have highlighted the serious nature ofC. difficile associated⁎ Corresponding author. Tel.: +1 608 263 6363(office), +1 608 263
3035(secretary); fax: +1 608 263 3104.
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doi:10.1016/j.jcf.2012.05.007disease (CDAD) in patients with CF. Yates et al. [4] suggested that
immunosuppression may play a role in the variable presentation of
CDAD and is likely to be important in the pathogenesis of the
disease by increasing the risk of colonization. As more patients
with severe CF lung disease undergo lung transplantation, failure
to diagnose CDAD in a timely manner may lead to high morbidity
and mortality [5]. Several risk factors have been shown to be
associated with CDAD in patients with CF including recent
antibiotic use, impaired immunity and decreased gastric acidity. A
genotype link (N1303K mutation) that may increase susceptibility
to CDAD has been described between CF and C. difficile [6].
However, despite the frequent antibiotic use in patients with CF,
the incidence of CDAD remains relatively low. However, with the
advent of lung transplantation, severe, often asymptomatic CDAD
cases may occur, and heightened vigilance and clinical suspicion
are required to make an early diagnosis, provide effective therapy,
and prevent complications.by Elsevier B.V. All rights reserved.
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We performed a retrospective chart review of ten cases of
CDAD that occurred between 1994 and 2010 in patients with CF
followed by our Adult CF Center. We specifically examined the
clinical course and management of 4 patients with severe disease,
of whom 2 were lung transplant recipients. Patient demographics
are given in Table 1, and outcomes are given in Table 2. This
research was approved by the University of Wisconsin Human
Subjects Committee. The University of Wisconsin—Madison
Health Sciences Minimal Risk IRB has granted exemption for
this research onMarch 7, 2012 under category 45 CFR 46.101(b)
[4].
3. Results
3.1. Pretransplant CF patients
3.1.1. Case 1
A 23-year-old female with chronic Pseudomonas aeruginosa
respiratory tract colonization was emergently transferred to our
hospital for evaluation of abdominal pain, nausea and vomiting that
began 1 week after having been discharged following treatment for
a CF respiratory exacerbation with intravenous tobramycin and
piperacillin/tazobactam. Upon admission to our facility she was
found to have disseminated intravascular coagulation and septic
shock thought to be related to fulminant colitis (Fig. 1). Empiric
treatment with intravenous and enteric vancomycin, as well as
intravenous metronidazole was initiated. She was taken to the OR
on the day of admission for subtotal colectomywith end ileostomy.
One week post-operatively she was transferred back to the
intensive care unit for cardiac arrythmia, hypotension and fever.
Recurrence of C. difficile infection in the rectal stump was
confirmed. Treatment with oral and rectal vancomycin and
intravenous metronidazole was initiated. She recovered and was
discharged, and she eventually had a successful re-anastomosis of
her ileum and rectum 6 months following her initial admission.
3.1.2. Case 2
A 31-year-old female with chronic respiratory tract P.
aeruginosa colonization presented with abdominal discomfort
and cramping for 4 days. She had received intravenous tobramy-
cin, aztreonam, and vancomycin 1 month prior to admission for a
CF respiratory exacerbation and had undergone endoscopic sinus
surgery. Her abdominal plain film showed an unremarkable air
pattern in the colon without signs to suggest toxic megacolon.
Stool culture could not be obtained on admission due to
constipation. On the basis of her clinical presentation, empiric
therapy with intravenous and oral vancomycin and metronidazoleTable 1
Patient demographics.
Parameter Transplant Non-transplant
Total N 4 6
Gender (M/F) 2/2 4/2
Mean age (years) 38.3 25.8was begun. The patient continued to experience abdominal pain,
edema and fever. Due to failure of conservative management and
development of an acute surgical abdomen she was taken to the
operating room for an exploratory laparotomy with subsequent
subtotal colectomy and end ileostomy. Pseudomembranous colitis
was clearly demonstrated in the resected colon. She developed
multi-organ failure and persistent shock post-operatively and was
given activated protein C therapy. Persistent ileus developed post-
operatively, and treatment with oral vancomycin and intravenous
metronidazole was continued throughout her hospitalization due
to concerns of persistent C. difficile infection. Eventually the
patient was transitioned to oral vancomycin alone as her bowel
function improved and was discharged from the hospital. She
underwent ileostomy takedown and reanastomosis of ileum to
rectum without complications 7 months later.
3.2. Lung transplant recipients
3.2.1. Case 3
A 37-year-old male with CF and chronic P. aeruginosa
colonization had an unremarkable clinical course following bilateral
lung transplantation and was started on standard tacrolimus-based
immunosuppression. Six months later he presented to the hospital
with persistent fatigue, nausea, vomiting and failure to thrive.
Hospital evaluation revealed a pancolitis that was thought to be
secondary toC. difficile although stool cultures were negative at that
time. The patient was treated with oral and intravenous vancomycin
and slowly improved. One month later he presented with diarrhea
and hypotension. A colonoscopy demonstrated edematous colonic
mucosa with the presence of diffuse pseudomembranes. Due to his
fulminant pancolitis and septic shock, a subtotal colectomy with
ileostomy was performed. Unfortunately, the patient was unable to
wean from the ventilator and continued to require intravenous
pressors for systemic hypotension. He was maintained on broad-
spectrum antibiotics despite his diagnosis ofC. difficile colitis due to
development of probable hospital-acquired pneumonia and gan-
grenous cholecystitis. He subsequently required a return to the
operating room due to persistent necrotizing cholecystitis and small
bowel obstruction. Due to lack of clinical improvement and
progression of multi-organ failure, he was transitioned to comfort
care and expired 8 days later.
3.2.2. Case 4
A 43-year-old female had several hospitalizations over a
period of several months for recurrent episodes of cholangitis
with cholelithiasis due to antibiotic-resistant P. aeruginosa
13 years post-bilateral lung transplant and 5 years post kidney
transplant. Her immunosuppression was cyclosporine-based,
and she received multiple broad-spectrum antibiotics including
intravenous vancomycin and colistimethate due to recurrent
cholangitis and was finally hospitalized for increasing abdom-
inal pain. Abdominal imaging demonstrated multiple dilated
bowel loops with wall thickening concerning for pseudomem-
branous colitis (Fig. 2). The patient was placed on intravenous
metronidazole and oral vancomycin. Her immunosuppressants
were held and the patient was given intravenous pulse-dose
steroids with 60 mg of intravenous solumedrol. She gradually
Table 2
Presenting symptoms, laboratory values and treatment modalities for all CF patients with CDAD.
Case Age Previous
antibiotic
pressure
Symptoms Initial WBC
count
Presence
of shock
Colectomy Treatment Recurrence Outcomes
1 23 Yes Cramping, loose
stools
3.6 Yes Yes Oral and rectal vancomycin, intravenous metronidazole Yes Survived
2 31 Yes Abdominal pain 12.1 Yes Yes Oral vancomycin and intravenous metronidazole Yes Survived
3 37 Yes Fatigue, diarrhea 6.1 Yes Yes Oral and intravenous vancomycin Yes Deceased
4 43 Yes Abdominal pain,
loose stools
4.5 No No Oral rifaximin, IVIG, oral and rectal vancomycin,
intravenous and oral metronidazole
Yes Survived
5 39 No Nausea, vomiting NA No No Oral vancomycin and intravenous metronidazole No Survived
6 56 Yes Diarrhea 8.4 No No Oral vancomycin and intravenous gancyclovir No Survived
7 42 Yes Loose stools 7.4 No No Oral vancomycin and intravenous gancyclovir No Survived
8 27 Yes Nausea, diarrhea 8.9 No No Oral vancomycin and intravenous gancyclovir No Survived
9 33 Yes Diarrhea 6.9 No No Oral vancomycin No Survived
10 26 Yes Vomiting, malaise,
diarrhea
11.2 Yes No Oral vancomycin and intravenous metronidazole No Deceased
Initial WBC count=white blood cell count×103/μl; NA = not available.
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three times daily, vancomycin 125 mg po 4 times daily for
1 month along with her post-transplant immunosuppressive and
antifungal medications. She continued to have frequent loose
stools and her symptoms worsened when her oral vancomycin
was stopped. One week later she was readmitted for suspected
recurrent CDAD. A repeat stool specimen was positive for C.
difficile. Given the refractory nature of her C. difficile infection
she was treated with a variety of regimens including oral
rifaximin, vancomycin enemas, intravenous immunoglobulin
course of 5 days, and intravenous metronidazole and fecal
transplant were considered. Liver transplantation was consid-
ered for her persistent cholangitis and hepatic cirrhosis if the C.
difficile infection cleared. However, both the cholangitis and
CDAD gradually cleared without the need for surgical
intervention, and she has not had any recurrence for over
2 years.Fig. 1. Abdominal computed tomogram of a patient with significant colonic
distention, bowel wall thickening and severe CDAD (case #1).4. Discussion
At present the interaction between C. difficile and immune
defenses is poorly understood, and the majority of patients who
have ingested C. difficile spores remain well. It has been shown
that patients who develop antibodies to C. difficile after the
bacterium is present in the bowel are less likely to develop CDAD.
While most cases of CDAD are mild to moderately severe, it is not
clear why some cases are fulminant, resulting in rapid progression
to severe and potentially fatal disease, and the transition of mild
disease to fatal infection is unpredictable. Systemic symptoms do
not appear to be derived from bacteremia, colonic perforation, or
ischemia, but from toxin-induced inflammatory mediators (inter-
leukin-8, macrophage-inflammatory protein-2, substance P, tumor
necrosis factor-alpha) released locally in the colon [7,8]. Age,
immune responsiveness, type of antibiotic exposure, anti-cancer
chemotherapy, strain differences in toxin production, and delays inFig. 2. Abdominal computed tomogram with colonic wall thickening, air fluid
levels and abdominal ascitic fluid in a patient with CDAD (case #4).
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Fig. 3. Comparison of shock, recurrence of CDAD and overall mortality in
transplanted versus non-transplanted CF patients (n=10).
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outcome of infection. Factors leading to relapse of CDAD are also
not well understood at present, but persistent imbalance of the
normal bowel bacterial biome is suspected to be one of many
possible causes of relapse. It is well known that C. difficile spores
persist in the colon following successful treatment of diarrhea [9].
Due to the alteration in the CFTR ion channel, patients often
present with atypical symptoms and the diagnosis of C. difficile
colitis can be missed. Often a patient is unable to provide a stool
sample to verify the findings of C. difficile colitis suggested by
diagnostic studies due to constipation. Despite heavy antimicro-
bial pressure, patients with CF have a low incidence of CDAD as
we have observed in our own institution. We describe a unique
presentation of four cases of patients with CDAD and CF due to
the recurrence of CDAD as an entity that is much harder to treat
and led to fulminant colitis and death in case 3.
Recurrent CDAD has been described in patients with CF, but
this entity is not fully characterized in the available literature and
presents a challenge to the clinician. Its occurrence can lead to
prolonged antimicrobial treatment, and novel treatment options
such as intravenous immunoglobulin or stool transplantation have
been given [10]. Table 2 demonstrates that 9 of our 10 patients had
previous (i.e. within a month of presentation) antibiotic exposure
that included intravenous tobramycin, as all of our patients had
known Pseudomonas respiratory infection. Additionally, two out
of the 10 patients presented with atypical symptoms, and 7 patients
presented with normal leukocyte count despite documented C.
difficile infection. We noted a similar incidence of shock in non-
transplanted patients versus lung transplant recipients (Fig. 3).
However, a lower recurrence rate was observed in the non-
transplant cohort. In addition we observed a clustering of CDAD
infection in cases 8–10, which was probably due to temporal
proximity of hospital admission and nosocomial spread of C.
difficile spores.
Two of the 10 cases had fatal outcome. Previous reports of
50%mortality as reported byYates et al. highlight the importance
of vigilance to detect the presence of C. difficile, and therapy for
C. difficile infection should be started immediately when it is
suspected to be present pending confirmation of the C. difficile
toxin in stool samples, as these patients can rapidly develop
critical illness and are at high risk of death [11,12].
Current literature recommends treatment with metronidazole
or vancomycin for 10–14 days, and significant improvement in
symptoms should be observed within 48–72 h [13]. In addition,
novel treatments such as intravenous immunoglobulin, oral
rifaximin and stool transplantation have been described.
Patients who do not respond to medical therapy will require
surgical intervention and long term antibiotic prophylaxis to
ensure disease-free survival. Radiographic modalities such as
computed tomography of the abdomen, abdominal magnetic
resonance imaging, and abdominal ultrasound have been used
as adjunct diagnostic tools in diagnosis of C. difficile colitis,
and abdominal imaging and endoscopic examination of the
colon were used to ascertain the diagnosis. We used abdominal
CT scanning as well as direct visualization of colonic mucosae
via enteroscopy to ascertain the diagnosis in 4 of the 10 patients
in our series.5. Summary and conclusions
We present a series of ten patients with CDAD that has led to
recurrence in four out of ten patients and subsequent development
of shock, sepsis and the need for surgical intervention. Although
we do not demonstrate a 50% mortality rate previously as
described in a lung transplant CF population, the role of
immunosuppression likely remains important in the pathogenesis
of disease by increasing the risk of colonization, as highlighted by
the series of Dallal et al. [14]. The presentation of CDAD can be
mistaken for other diagnoses such as distal intestinal obstruction
syndrome (DIOS), meconium ileus, appendicitis, pancreatitis,
constipation, gastrointestinal malignancy, ovarian cyst, volvulus,
bowel adhesions, intussusception and inflammatory bowel disease
states. Despite the broad differential diagnosis, a high index of
clinical suspicion and radiographic modalities such as computed
abdominal scans and magnetic resonance imaging allow the
clinician to make an accurate diagnosis of CDAD. As demon-
strated in our series, despite appropriate medical and surgical
treatment CDAD may reoccur and lead to significant clinical
morbidity and mortality. This specifically is demonstrated by
increased rates of recurrence in the lung transplant population in
our series as 50% of CDAD cases in lung transplant patients
recurred however only 33% of non-lung transplant patients
demonstrated recurrence as demonstrated in Fig. 3. This study
corroborates the previous data by Dallal et al. [14], showing that
immunosuppression as part of lung transplantation and/or
previous history of treatment for C. difficile colitis increases the
risks of CDAD recurrence and possibly mortality and morbidity.
Therefore, we propose that empiric anti C. difficile treatment
should be used in lung transplant patients with previous history of
CDAD despite absence of symptoms during hospitalizations.
Further studies are necessary to confirm this conclusion.
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